Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Finance

Spring cleaning

SpringWorks provides a development path for pharma's de-prioritized assets

Virginia Li, Staff Writer
September 29, 2017 9:00 PM UTC

SpringWorks Therapeutics LLC aims to partner with pharmas and big biotechs seeking a development path for clinical stage assets outside of their core therapeutic areas. With its tranched $103 million series A round, the newco will advance existing programs spun out of Pfizer Inc. (NYSE:PFE) while it continues to expand its pipeline.

Bain Capital Life Sciences, Bain Capital Double Impact and OrbiMed led the tranched round, joined by Pfizer and LifeArc. Details regarding the tranches are not disclosed. ...

Get Unlimited Access
Continue reading with a free trial.
Start a Free TrialLog In
Or Purchase This Article

BCIQ Company Profiles

Pfizer Inc.

Springworks Therapeutics Inc.